Mold-Tek Pack. Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Industrial Products | Market Cap: ₹2.4K Cr
Volume growth target of 10% to 12% for the full year, despite challenges like the war and raw material issues. EBITDA per kg is expected to grow around 18% to 20%, driven by product mix changes, operational efficiencies, and consolidation.
From Mold-Tek Pack.'s Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Price
₹711
Market Cap
₹2.4K Cr
P/E Ratio
31.0
Revenue Rank
Margin Rank
How does Mold-Tek Pack. rank in Industrial Products?
Compare Mold-Tek Pack. against every Industrial Products company this quarter on revenue, margins and earnings-call signals.
Mold-Tek Pack. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹238 Cr, net profit ₹21 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →Volume growth target of 10% to 12% for the full year, despite challenges like the war and raw material issues.
- →Paint segment expected to grow in the 10% to 15% range, with signs of acceleration, driven by increased IML adoption and capacity utilization.
- →Food & FMCG and pharma segments growing rapidly, with Food & FMCG projected CAGR of 18%-20% and pharma at 40%-50% CAGR over 3-4 years.
- →Pharma currently about 3.5% of overall sales but expected to grow significantly, aiming for INR 50-55 crores revenue, a ~50% YoY increase.
- →EBITDA growth expected at 18%-20%, outpacing volume growth due to profitable product mix and operational efficiencies.
- →Capacity expansion planned at 10%-12% annually to capture growth opportunities.
- →Emphasis on EBITDA per kg as key profitability metric rather than just volume.
📈 Profitability & Margins
Rank 3- →EBITDA per kg is expected to grow around 18% to 20%, driven by product mix changes, operational efficiencies, and consolidation.
- →Volume growth is expected to be close to 10% going forward.
- →The company anticipates maintaining around 19%-20% EBITDA growth for the rest of the year.
- →EBITDA per kg, which is a key profitability metric, is projected to remain strong, potentially improving further with increased automation and continued efficiencies.
- →For the full year, the company aims to surpass previous EBITDA targets (earlier INR42-43), now targeting around INR44-45 per kg.
- →Strong growth in pharma (+40%) and Food & FMCG segments is expected to support higher margin growth compared to volume growth.
- →Paint segment volume growth is expected in the 10%-15% range, supporting overall growth.
- →The company expects incremental EBITDA per kg growth to normalize but remain better than the previous year due to cost advantages and consolidation benefits.
🏗️ Capital Expenditure Plans
Yes- →Q1 FY27 capex was around INR 20-22 crores.
- →Total capex for FY27 is expected to be about INR 90 crores.
- → - INR 25-30 crores allocated for pharma.
- → - The balance for balancing and replacement.
- →For medical devices (dosing pens and others), initial investment expected around INR 25-30 crores, including land and machinery.
- →New construction ongoing: 25,000 sq ft facility for ophthalmic products to be completed in 6 months.
- →No new consolidation of units planned beyond Hyderabad facility; focus on automation and efficiency improvements.
- →Future capex includes adding 10-12% capacity annually at Cheyyar, Panipat, and Mahad units to meet growth.
- →Potential strategic moves into white goods, electronics, and semiconductor packaging are at an early drawing board stage.
💰 Fundraising & Capital Structure
No information- →There is no explicit mention of any new fundraising through debt or equity in the provided transcript.
- →J. Lakshman Rao mentioned that the finance cost increased primarily due to increased raw material costs and higher working capital needs, not due to increased term loans or fresh debt.
- →Current working capital stands at INR125 crores, up from INR110-112 crores in March, reflecting higher raw material inventory but expected to stabilize.
- →Capex for FY27 is planned around INR90 crores, funded presumably from internal accruals or existing resources.
- →No direct references were made to raising equity or additional debt for expansion or working capital.
- →The company is open to partnerships and tie-ups (e.g., in medical devices), but no explicit fundraising tied to these plans is mentioned.
📋 Order Book & Pipeline
Yes- →Currently, Mold-Tek Packaging Limited has orders from around 20-25 pharma companies.
- →Additionally, approximately 10 more pharma companies are scheduled to visit and potentially place orders in the coming weeks or months.
- →The company is actively expanding in pharma, medical devices, Food & FMCG sectors aside from traditional paint clientele.
- →No specific quantitative value for the order book or pending orders is provided in the transcript, but increasing client interest and new visits indicate a growing order pipeline.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Mold-Tek Pack. Q1 FY27 results?
Volume growth target of 10% to 12% for the full year, despite challenges like the war and raw material issues. EBITDA per kg is expected to grow around 18% to 20%, driven by product mix changes, operational efficiencies, and consolidation.
What is Mold-Tek Pack. share price analysis?
Mold-Tek Pack. currently shows a below-average growth signal. The stock trades at a P/E of 31.0 with a market cap of ₹2,356 Cr. Investors should review the full earnings analysis for detailed insights.
Is Mold-Tek Pack. planning capital expenditure?
Q1 FY27 capex was around INR 20-22 crores.
Keep Mold-Tek Pack. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.